tbuckley/cabot-search huggingface dataset:
Abstract 238: Automating Medical Record Matching: A Key Component of an Automated Cardiac Arrest Registry
Authors: Samuel McDonald, Raymond Fowler, Pamela Owens, Susanne May, Heather Herren, Ahamed H Idris
Journal: Circulation (2019)

Introduction: An automated registry for out-of-hospital cardiac arrest can facilitate cardiac arrest research and emergency medical services (EMS) and community health quality improvement programs. A key element of a cardiac arrest registry is outcome, especially survival to hospital discharge, which is usually obtained from the hospital medical record. A crucial step in capturing survival data automatically is being able to reliably match EMS patient care reports with hospital medical records. Objective: To determine the accuracy of a probabilistic record-linkage approach to match EMS and hospital encounters and identify barriers of automation. Methods: This is a prospective feasibility study from the Dallas Fort-Worth Center for Resuscitation Research. Our cardiac arrest registry was part of the Resuscitation Outcomes Consortium (ROC) Epistry from 2006 to 2016. Since 2016, we maintained it separately from the ROC and have since enrolled over 20,000 cases. Record linkage was performed using demographic data of encounters from a single EMS agency within the registry and a community hospital in Dallas where these were transported from January 2017 to May 2018. An expectation maximization algorithm to aid in discerning matches and nonmatches was performed using the R package RecordLinkage identifying record pairs as a match, non-match, or possible match based on a pre-determined threshold. Match and Possible Match pairs were manually reviewed to assess the algorithm’s accuracy. Results: The EMS and hospital data sets had 67 and 6,050 unique encounters, respectively. The record linkage algorithm identified 40 EMS encounters as having a match (60%), 12 with a possible match (18%), and 15 with no identified match (22%). After manual review, the algorithm had a positive predictive value (PPV) of 100% (40/40) for the match group with a sensitivity of 60%. Conclusions: Applying probabilistic linkage to aid in automating a cardiac arrest registry was successful in linking over half of the EMS encounters with a PPV of 100%. When reviewing the unmatched encounters, many were adjacent to each other when sorted by time suggesting the poor sensitivity is more likely a reflection of the hospital’s data collection method as opposed to the linkage methodology.
Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy Vs the Same Concomitant Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LASCCHN)
Authors: W. El-Sadda, I. Abdel Halim, K. Abul Khair, R. Abdel Latif
Journal: Annals of Oncology (2012)
Neoadjuvant Treatment in Rectal Cancer: National Institute of Cancer from Brazil Experience
Authors: L.C.M. Aquino, M.S. Rossi, P.C. Val, M.A. Oliveira, T. Matta-Castro, D. Herchenhorn, C.G. Duque, R.D.A. Gil, B.S.V. Pereira
Journal: Annals of Oncology (2012)
Clinical Implication of Epithelial to Mesenchymal Transition in Hepatocellular Carcinoma
Authors: T. Fujii, S. Yamada, N. Okumura, B.C. Fuchs, M. Suenaga, G. Nakayama, H. Sugimoto, S. Takeda, K.K. Tanabe, Y. Kodera
Journal: Annals of Oncology (2012)
Trends in the Adoption of Robotic Surgery for Common Surgical Procedures
Authors: Kyle H. Sheetz, Jake Claflin, Justin B. Dimick
Journal: JAMA Network Open (2020)

<h3>Importance</h3> Increasing use of robotic surgery for common surgical procedures with limited evidence and unclear clinical benefit is raising concern. Analyses of population-based trends in practice and how hospitals' acquisition of robotic surgical technologies is associated with their use are limited. <h3>Objective</h3> To characterize trends in the use of robotic surgery for common surgical procedures. <h3>Design, Setting, and Participants</h3> This cohort study used clinical registry data from Michigan from January 1, 2012, through June 30, 2018. Trends were characterized in the use of robotic surgery for common procedures for which traditional laparoscopic minimally invasive surgery was already considered a safe and effective approach for most surgeons when clinically feasible. A multigroup interrupted time series analysis was performed to determine how procedural approaches (open, laparoscopic, and robotic) change after hospitals launch a robotic surgery program. Data were analyzed from March 1 through April 19, 2019. <h3>Exposures</h3> Initiation of robotic surgery. <h3>Main Outcomes and Measures</h3> Procedure approach (ie, robotic, open, or laparoscopic). <h3>Results</h3> The study cohort included 169 404 patients (mean [SD] age, 55.4 [16.9] years; 90 595 women [53.5%]) at 73 hospitals. The use of robotic surgery increased from 1.8% in 2012 to 15.1% in 2018 (8.4-fold increase; slope, 2.1% per year; 95% CI, 1.9%-2.3%). For certain procedures, the magnitude of the increase was greater; for example, for inguinal hernia repair, the use of robotic surgery increased from 0.7% to 28.8% (41.1-fold change; slope, 5.4% per year; 95% CI, 5.1%-5.7%). The use of robotic surgery increased 8.8% in the first 4 years after hospitals began performing robotic surgery (2.8% per year; 95% CI, 2.7%-2.9%). This trend was associated with a decrease in laparoscopic surgery from 53.2% to 51.3% (difference, −1.9%; 95% CI, −2.2% to −1.6%). Before adopting robotic surgery, hospitals' use of laparoscopic surgery increased 1.3% per year. After adopting robotic surgery, the use of laparoscopic surgery declined 0.3% (difference in trends, −1.6%; 95% CI, −1.7% to −1.5%). <h3>Conclusions and Relevance</h3> These results suggest that robotic surgery has continued to diffuse across a broad range of common surgical procedures. Hospitals that launched robotic surgery programs had a broad and immediate increase in the use of robotic surgery, which was associated with a decrease in traditional laparoscopic minimally invasive surgery.
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma
Authors: Patrizia Mondello, Saber Tadros, Matt Teater, Lorena Fontan, Aaron Y. Chang, Neeraj Jain, Haopeng Yang, Shailbala Singh, Hsia-Yuan Ying, Chi-Shuen Chu, Man Chun John Ma, Eneda Toska, Stefan Alig, Matthew Durant, Elisa de Stanchina, Sreejoyee Ghosh, Anja Mottok, Loretta Nastoupil, Sattva S. Neelapu, Oliver Weigert, Giorgio Inghirami, José Baselga, Anas Younes, Cassian Yee, Ahmet Dogan, David A. Scheinberg, Robert G. Roeder, Ari M. Melnick, Michael R. Green
Journal: Cancer Discovery (2020)

CREBBP mutations are highly recurrent in B-cell lymphomas and either inactivate its histone acetyltransferase (HAT) domain or truncate the protein. Herein, we show that these two classes of mutations yield different degrees of disruption of the epigenome, with HAT mutations being more severe and associated with inferior clinical outcome. Genes perturbed by CREBBP mutation are direct targets of the BCL6-HDAC3 onco-repressor complex. Accordingly, we show that HDAC3-selective inhibitors reverse CREBBP-mutant aberrant epigenetic programming, resulting in: (i) growth inhibition of lymphoma cells through induction of BCL6 target genes such as CDKN1A and (ii) restoration of immune surveillance due to induction of BCL6-repressed IFN pathway and antigen-presenting genes. By reactivating these genes, exposure to HDAC3 inhibitors restored the ability of tumor-infiltrating lymphocytes to kill DLBCL cells in an MHC class I and II-dependent manner, and synergized with PD-L1 blockade in a syngeneic model in vivo. Hence, HDAC3 inhibition represents a novel mechanism-based immune epigenetic therapy for CREBBP-mutant lymphomas. SIGNIFICANCE: We have leveraged the molecular characterization of different types of CREBBP mutations to define a rational approach for targeting these mutations through selective inhibition of HDAC3. This represents an attractive therapeutic avenue for targeting synthetic vulnerabilities in CREBBP-mutant cells in tandem with promoting antitumor immunity.This article is highlighted in the In This Issue feature, p. 327.
Feasibility Trial of Postoperative Adjuvant Chemotherapy with S-1, an Oral Fluoropyrimidine, for Elderly Patients with Non-Small Cell Lung Cancer: Report of the Lung Oncology Group in KYUSHU (LOGIK) Protocol 0901
Authors: N. Ebi, R. Maruyama, J. Kishimoto, K. Tsuruno, M. Kato, T. Yano, Y. Nagamatsu, S. Tsukamoto, S. Akamine, S. Saeki, Y. Ichinose
Journal: Annals of Oncology (2012)
What time words teach us about children's acquisition of the temporal reasoning system
Authors: Katharine A. Tillman
Journal: Behavioral and Brain Sciences (2019)

Abstract Here I consider the possible role of the temporal updating system in the development of the temporal reasoning system. Using evidence from children's acquisition of time words, I argue that abstract temporal concepts are not built from primitive representations of time. Instead, I propose that language and cultural learning provide the primary sources of the temporal reasoning system.
P-0165 Intra-Abdominal Sarcomas: Report of 11 Cases Treated in a Moroccan Medical Oncology Unit
Authors: Karima Oualla, Fatima Zahra El M'Rabet, Nezar Bouyahia, Sami Aziz Brahmi, Samia Arifi, Nawfel Mellas, Omar El Mesbahi
Journal: Annals of Oncology (2012)
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Authors: Helena Costa Verdera, Klaudia Kuranda, Federico Mingozzi
Journal: Molecular Therapy (2020)

Gene therapy with adeno-associated virus (AAV) vectors has demonstrated safety and long-term efficacy in a number of trials across target organs, including eye, liver, skeletal muscle, and the central nervous system. Since the initial evidence that AAV vectors can elicit capsid T cell responses in humans, which can affect the duration of transgene expression, much progress has been made in understanding and modulating AAV vector immunogenicity. It is now well established that exposure to wild-type AAV results in priming of the immune system against the virus, with development of both humoral and T cell immunity. Aside from the neutralizing effect of antibodies, the impact of pre-existing immunity to AAV on gene transfer is still poorly understood. Herein, we review data emerging from clinical trials across a broad range of gene therapy applications. Common features of immune responses to AAV can be found, suggesting, for example, that vector immunogenicity is dose-dependent, and that innate immunity plays an important role in the outcome of gene transfer. A range of host-specific factors are also likely to be important, and a comprehensive understanding of the mechanisms driving AAV vector immunogenicity in humans will be key to unlocking the full potential of in vivo gene therapy.
IL-33/ST2 pathway regulates neutrophil migration and predicts outcome in patients with severe alcoholic hepatitis
Authors: Florent Artru, Mohamed Bou Saleh, François Maggiotto, Guillaume Lassailly, Massih Ningarhari, Julie Demaret, Line-Carolle Ntandja-Wandji, Jean-Paul Pais de Barros, Julien Labreuche, Elodie Drumez, Doumet Georges Helou, Sébastien Dharancy, Emilie Gantier, Axel Périanin, Sylvie Chollet-Martin, Ramon Bataller, Philippe Mathurin, Laurent Dubuquoy, Alexandre Louvet
Journal: Journal of Hepatology (2020)
Correction to: Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab
Authors: S.M. Swain, A. Schneeweiss, L. Gianni, J.J. Gao, A. Stein, M. Waldron-Lynch, S. Heeson, M.S. Beattie, B. Yoo, J. Cortes, J. Baselga
Journal: Annals of Oncology (2019)
Surfactant Expression Defines an Inflamed Subtype of Lung Adenocarcinoma Brain Metastases that Correlates with Prolonged Survival
Authors: Kolja Pocha, Andreas Mock, Carmen Rapp, Steffen Dettling, Rolf Warta, Christoph Geisenberger, Christine Jungk, Leila R. Martins, Niels Grabe, David Reuss, Juergen Debus, Andreas von Deimling, Amir Abdollahi, Andreas Unterberg, Christel C. Herold-Mende
Journal: Clinical Cancer Research (2020)

Abstract Purpose: To provide a better understanding of the interplay between the immune system and brain metastases to advance therapeutic options for this life-threatening disease. Experimental Design: Tumor-infiltrating lymphocytes (TIL) were quantified by semiautomated whole-slide analysis in brain metastases from 81 lung adenocarcinomas. Multi-color staining enabled phenotyping of TILs (CD3, CD8, and FOXP3) on a single-cell resolution. Molecular determinants of the extent of TILs in brain metastases were analyzed by transcriptomics in a subset of 63 patients. Findings in lung adenocarcinoma brain metastases were related to published multi-omic primary lung adenocarcinoma The Cancer Genome Atlas data (n = 230) and single-cell RNA-sequencing (scRNA-seq) data (n = 52,698). Results: TIL numbers within tumor islands was an independent prognostic marker in patients with lung adenocarcinoma brain metastases. Comparative transcriptomics revealed that expression of three surfactant metabolism-related genes (SFTPA1, SFTPB, and NAPSA) was closely associated with TIL numbers. Their expression was not only prognostic in brain metastasis but also in primary lung adenocarcinoma. Correlation with scRNA-seq data revealed that brain metastases with high expression of surfactant genes might originate from tumor cells resembling alveolar type 2 cells. Methylome-based estimation of immune cell fractions in primary lung adenocarcinoma confirmed a positive association between lymphocyte infiltration and surfactant expression. Tumors with a high surfactant expression displayed a transcriptomic profile of an inflammatory microenvironment. Conclusions: The expression of surfactant metabolism-related genes (SFTPA1, SFTPB, and NAPSA) defines an inflamed subtype of lung adenocarcinoma brain metastases characterized by high abundance of TILs in close vicinity to tumor cells, a prolonged survival, and a tumor microenvironment which might be more accessible to immunotherapeutic approaches.
Precursors for Nonlymphoid-Tissue Treg Cells Reside in Secondary Lymphoid Organs and Are Programmed by the Transcription Factor BATF
Authors: Michael Delacher, Charles D. Imbusch, Agnes Hotz-Wagenblatt, Jan-Philipp Mallm, Katharina Bauer, Malte Simon, Dania Riegel, André F. Rendeiro, Sebastian Bittner, Lieke Sanderink, Asmita Pant, Lisa Schmidleithner, Kathrin L. Braband, Bernd Echtenachter, Alexander Fischer, Valentina Giunchiglia, Petra Hoffmann, Matthias Edinger, Christoph Bock, Michael Rehli, Benedikt Brors, Christian Schmidl, Markus Feuerer
Journal: Immunity (2020)

Specialized regulatory T (Treg) cells accumulate and perform homeostatic and regenerative functions in nonlymphoid tissues. Whether common precursors for nonlymphoid-tissue Treg cells exist and how they differentiate remain elusive. Using transcription factor nuclear factor, interleukin 3 regulated (Nfil3) reporter mice and single-cell RNA-sequencing (scRNA-seq), we identified two precursor stages of interleukin 33 (IL-33) receptor ST2-expressing nonlymphoid tissue Treg cells, which resided in the spleen and lymph nodes. Global chromatin profiling of nonlymphoid tissue Treg cells and the two precursor stages revealed a stepwise acquisition of chromatin accessibility and reprogramming toward the nonlymphoid-tissue Treg cell phenotype. Mechanistically, we identified and validated the transcription factor Batf as the driver of the molecular tissue program in the precursors. Understanding this tissue development program will help to harness regenerative properties of tissue Treg cells for therapy.
O-0029 Prognostic Impact of DNA Mismatch Repair Status and BRAF Mutations in Stage III Colon Cancer Patients Treated in a Phase III Study of Adjuvant Folfox Alone or Combined with Cetuximab: NCCTG N0147
Authors: Frank A. Sinicrope, Michelle R. Mahoney, Thomas C. Smyrk, Stephen N. Thibodeau, Richard M. Goldberg, G.D. Nelson, Daniel J. Sargent, Steven R. Alberts
Journal: Annals of Oncology (2012)
Cabazitaxel Plus Prednisone (CBZP) in Metastatic Castration-Resistant Prostate Cancer (MCRPC) Patients Previously Treated with Docetaxel (D): Efficacy and Safety Results from Early-Access Program (EAP) Single Site Experience
Authors: P. Rescigno, C. D'Aniello, P. Federico, L. Puglia, A. Petremolo, C. Cavaliere, C. Buonerba, S. De Placido, G. Di Lorenzo
Journal: Annals of Oncology (2012)
Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma
Authors: Jin Jie, Siguo Hao, Songfu Jiang, Zonghai Li, Min Yang, Wenhao Zhang, Kang Yu, Jun Xiao, Haitao Meng, Liyuan Ma, Mingxia He, Wei WANG, Xin Huang, Linjun Chen, Chongyun Xing, Daijing Yuan, Shasha Wang, Rong Tao, Lihui Dai, Hong Ma
Journal: Blood (2019)
Fluorodeoxyglucose Positron Emission Tomography for Evaluating Early Response During Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma
Authors: C.-C. Lin, C.-H. Hsu, K.-Y. Tzen, J.C. Cheng, J.-M. Lee, H.-P. Wang, P.-M. Huang, F.-M. Hsu, W.-W. Chen, T.-C. Huang, A.-L. Cheng
Journal: Annals of Oncology (2012)
An Investigation into P/B-Maintenance Therapy Following Combined Therapy with Carboplatin (C) + Pemetrexed (P) + Bevacizumab (B) as the Primary Treatment against Non-SQ NSCLC
Authors: H. Nakagawa, K. Yamamoto, A. Simoyama, Y. Kubota, S. Ota
Journal: Annals of Oncology (2012)
Visceral adipose NLRP3 impairs cognition in obesity via IL-1R1 on CX3CR1+ cells
Authors: De-Huang Guo, Masaki Yamamoto, Caterina M. Hernandez, Hesam Khodadadi, Babak Baban, Alexis M. Stranahan
Journal: Journal of Clinical Investigation (2020)

Induction of the inflammasome protein cryopyrin (NLRP3) in visceral adipose tissue (VAT) promotes release of the proinflammatory cytokine IL-1β in obesity. Although this mechanism contributes to peripheral metabolic dysfunction, effects on the brain remain unexplored. We investigated whether visceral adipose NLRP3 impairs cognition by activating microglial IL-1 receptor 1 (IL-1R1). After observing protection against obesity-induced neuroinflammation and cognitive impairment in NLRP3-KO mice, we transplanted VAT from obese WT or NLRP3-KO donors into lean recipient mice. Transplantation of VAT from a WT donor (TRANSWT) increased hippocampal IL-1β and impaired cognition, but VAT transplants from comparably obese NLRP3-KO donors (TRANSKO) had no effect. Visceral adipose NLRP3 was required for deficits in long-term potentiation (LTP) in transplant recipients, and LTP impairment in TRANSWT mice was IL-1 dependent. Flow cytometric and gene expression analyses revealed that VAT transplantation recapitulated the effects of obesity on microglial activation and IL-1β gene expression, and visualization of hippocampal microglia revealed similar effects in vivo. Inducible ablation of IL-1R1 in CX3CR1-expressing cells eliminated cognitive impairment in mice with dietary obesity and in transplant recipients and restored immunoquiescence in hippocampal microglia. These results indicate that visceral adipose NLRP3 impairs memory via IL-1–mediated microglial activation and suggest that NLRP3/IL-1β signaling may underlie correlations between visceral adiposity and cognitive impairment in humans.
Trends in Cesarean Delivery Rates in China, 2008-2018
Authors: Hong-tian Li, Susan Hellerstein, Yu-bo Zhou, Jian-meng Liu, Jan Blustein
Journal: JAMA (2020)

2.FDA updates and press announcements on angiotensin ii receptor blocker (ARB) recalls (valsartan, losartan, and irbesartan).US Food and Drug Administration website.https://www.fda.gov/drugs/drug-safety-andavailability/fda-updates-and-press-announcements-angiotensin-ii-receptorblocker-arb-recalls-valsartan-losartan.Accessed August 9, 2019.3. FDA statement on the FDA's ongoing investigation into valsartan and ARB class impurities and the agency's steps to address the root causes of the safety issues.US Food and Drug Administration website.https://www.fda.gov/newsevents/press-announcements/fda-statement-fdas-
Survey on Models of Integration of Oncology and Palliative Care (PC) in Italian Oncology Units Esmo Designated Centers
Authors: V. Zagonel, C. Mastromauro, M. Ciaparrone, V. Franciosi, L. Verna, C. Moro, Z.C. Di Rocco, A.A. Martoni, L. Cavanna, G. Farina
Journal: Annals of Oncology (2012)
NP Chemotherapy Plus Endostar Compared with NP Alone as First-Line Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer: A Retrospective Study
Authors: M. Zhao, H. Deng, B. Jin, P. Yu, Y. Luo, X. Qu, Y. Teng, Q. Guan, Y. Liu
Journal: Annals of Oncology (2012)
Keep That Same Energy
Authors: Alexandra M. Sims
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Phase II Study of Cisplatin (P), S-1 (S) and Concurrent Thoracic Radiotherapy (TRT) for Locally Advanced Non-Small-Cell Lung Cancer (LA-NSCLC): Okayama Lung Cancer Study Group Trial 0501
Authors: N. Nogami, T. Kozuki, Y. Segawa, T. Shinkai, T. Maeda, H. Ueoka, S. Harita, S. Kuyama, S. Hosokawa, K. Gemba, M. Takemoto, N. Takigawa, M. Tabata, M. Tanimoto, K. Kiura
Journal: Annals of Oncology (2012)
O-0019 Severe Fluoropyrimidines Toxicities: A Simple and Effective Way to Avoid Them. Screen Effectively for DPD Deficiencies.
Authors: Boisdron Michele-Celle, Olivier Capitain, Jean-Philippe Metges, Véronique Guerin-Meyer, Roger Faroux, Claire Stampfli, Tamara Matysiak-Budnik, Chantal Leguellec, Erick Gamelin, Alain Morel
Journal: Annals of Oncology (2012)
O-0017 Randomized Phase II Study Evaluating Ufox Plus Cetuximab Versus Folfox4 Plus Cetuximab as First-Line Therapy in Metastatic Colorectal Cancer: Future
Authors: Jean-Yves Douillard, Tomasz Zemelka, Georgios Fountzilas, Carlo Barone, Michael Schlichting, S. Peter Eggleton, Vichien Srimuninnimit
Journal: Annals of Oncology (2012)
Efficacy and safety of a comprehensive educational antimicrobial stewardship program focused on antifungal use
Authors: Guillermo Martín-Gutiérrez, Germán Peñalva, Maite Ruiz-Pérez de Pipaón, Manuela Aguilar, María Victoria Gil-Navarro, José Luis Pérez-Blanco, María Antonia Pérez-Moreno, Rosario Amaya-Villar, Carmen Ferrándiz-Millón, María L. Gascón, Walter A. Goycochea-Valdivia, Manuel E. Jiménez-Mejías, María Dolores Navarro, José A. Lepe, Rocío Alvarez-Marín, Olaf Neth, Ana B. Guisado-Gil, Carmen Infante-Domínguez, José Molina, José M. Cisneros
Journal: Journal of Infection (2020)
P1.26 Micrornas' Expression Profile and their Correlation with Clinical Outcome in head and Neck Squamous Cell Carcinoma
Authors: F. Ganci, N. Bossel, A. Sacconi, G. Fontemaggi, V. Manciocco, I. Sperduti, E. Falvo, L. Strigari, R. Covello, P. Muti, S. Strano, G. Spriano, E. Domany, G. Blandino
Journal: Annals of Oncology (2012)
Clinical Significance of Microrna Expression as a Prognostic Factor in Early N+ Breast Cancer (BC)
Authors: E. Ciruelos, G.A. De Velasco, A. Gamez, C. Castañeda, J. Sepúlveda, I. Ghanem, H. Cortes-Funes, J.A. Fresno
Journal: Annals of Oncology (2012)